We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

59 hedge funds and large institutions have $133M invested in LogicBio Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 6

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

36% more capital invested

Capital invested by funds: $97.5M → $133M (+$35.2M)

16% more funds holding

Funds holding: 51 → 59 (+8)

Holders
59
Holders Change
+8
Holders Change %
+15.69%
% of All Funds
1.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
26
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$13.4M
2
Franklin Resources
Franklin Resources
California
+$6.01M
3
EC
EcoR1 Capital
California
+$5.18M
4
SC
Samlyn Capital
New York
+$4.31M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.35M

Top Sellers

Rank Fund Capital Flow
1
JG
Jefferies Group
New York
-$308K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$288K
3
Russell Investments Group
Russell Investments Group
United Kingdom
-$250K
4
JP Morgan Chase
JP Morgan Chase
New York
-$143K
5
TRCT
Tower Research Capital (TRC)
New York
-$66.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$64.6M +$13.4M +2,000,000 +31%
Franklin Resources
2
Franklin Resources
California
$12.2M +$6.01M +898,644 +128%
SC
3
Samlyn Capital
New York
$10.8M +$4.31M +643,551 +83%
BlackRock
4
BlackRock
New York
$6.89M +$1.23M +183,768 +26%
Vanguard Group
5
Vanguard Group
Pennsylvania
$6.01M +$3.03M +453,636 +136%
EC
6
EcoR1 Capital
California
$5.91M +$5.18M +775,000 New
LPC
7
Lion Point Capital
New York
$3.81M – – –
Fidelity Investments
8
Fidelity Investments
Massachusetts
$3.81M +$3.35M +500,000 New
BBA
9
Baker Bros. Advisors
New York
$3.44M +$3.02M +451,478 New
JP Morgan Chase
10
JP Morgan Chase
New York
$2.18M -$143K -21,313 -7%
PVI
11
Pura Vida Investments
New York
$1.91M +$1.67M +250,000 New
Verition Fund Management
12
Verition Fund Management
Connecticut
$1.75M +$1.54M +229,834 New
State Street
13
State Street
Massachusetts
$1.64M +$382K +57,093 +36%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$1.57M +$463K +69,237 +51%
Northern Trust
15
Northern Trust
Illinois
$1.39M +$315K +47,058 +35%
BCM
16
Bridgeway Capital Management
Texas
$644K – – –
Millennium Management
17
Millennium Management
New York
$451K +$291K +43,554 +280%
Bank of New York Mellon
18
Bank of New York Mellon
New York
$427K +$178K +26,633 +91%
FT
19
Fiduciary Trust
Massachusetts
$290K – – –
Charles Schwab
20
Charles Schwab
California
$261K +$55.4K +8,278 +32%
Citadel Advisors
21
Citadel Advisors
Florida
$248K +$217K +32,430 New
N
22
Nuveen
North Carolina
$239K +$11.2K +1,672 +6%
Goldman Sachs
23
Goldman Sachs
New York
$231K +$6.53K +976 +3%
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$189K +$44.6K +6,661 +37%
Morgan Stanley
25
Morgan Stanley
New York
$181K +$111K +16,607 +233%
1
2 3

LOGC Hedge Fund Activity: Q4 2020 in Review

59 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q4 2020, worth a combined $133M — up 36% from $97.5M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new LOGC positions and 5 closed out — a net gain of 8 holders — while 26 added to existing stakes and 6 trimmed.

The largest buyer was OrbiMed, adding an estimated $13.4M. The largest seller was Jefferies Group, exiting entirely with an estimated $308K sold.

  • 59 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q4 2020, up from 51 in Q3 2020.
  • Funds reported $133M of LogicBio Therapeutics, Inc. Common Stock stock for Q4 2020, up 36% quarter-over-quarter.
  • 13 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q4 2020 and 5 closed out, a net change of +8 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q4 2020 was OrbiMed, an estimated $13.4M added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q4 2020 was Jefferies Group, an estimated $308K sold.

Based on aggregated 13F filings for Q4 2020.